Abstract
No public abstract is available from the verified source records.
Curtis A. Lachowiez, Courtney Denton Dinardo
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Azacitidine and venetoclax in previously untreated acute myeloid leukemia
10.1056/nejmoa2012971 · 2020
Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia
10.1002/ajh.27246 · 2024
Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML
10.1182/blood.2024027217 · 2025
Results from paradigm-a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia
10.1182/blood-2025-6 · 2025
Mayo genetic risk models for newly diagnosed acute myeloid leukemia treated with venetoclax+ hypomethylating agent
10.1002/ajh.27564 · 2025
Impact of F LT3 mutation on outcomes after venetoclax and azacitidine for patients with treatment-naive acute myeloid leukemia
10.1158/1078-0432.ccr-21-3405 · 2022
Genomic classification and prognosis in acute myeloid leukemia
10.1056/nejmoa1516192 · 2016
Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia
10.1182/bloodadvances.2022009010 · 2023
Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine
10.1182/blood.2024024944 · 2024
Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML
10.1056/nejmoa1716984 · 2018
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
10.1182/blood-2017-04-779405 · 2017
Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML
10.1056/nejmoa1902688 · 2019
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia
10.1038/s41586-023-05812-3 · 2023
Outcomes of frontline triplet regimens with a hypomethylating agent, venetoclax, and isocitrate dehydrogenase inhibitor for intensive chemotherapy–ineligible patients with isocitrate dehydrogenase–mutated AML
10.1200/jco-25-00640 · 2025
Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML
10.1182/bloodadvances.2025016399 · 2025
Impact of venetoclax and azacitidine in treatment-naïve patients with acute myeloid leukemia and IDH1/2 mutations
10.1158/1078-0432.ccr-21-3467 · 2022
Measurable residual disease response and prognosis in treatment-naïve acute myeloid leukemia with venetoclax and azacitidine
10.1200/jco.21.01546 · 2022
Azacitidine, venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3-mutated AML
10.1200/jco.23.01911 · 2024
Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial
10.1016/s0140-6736(23)00464-6 · 2023
Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis
10.1001/jamaoncol.2020.4600 · 2020
Venetoclax (VEN) and azacitidine (AZA) with gilteritinib (GILT) in patients with newly diagnosed (ND) FLT3mut+ Acute Myeloid Leukemia (AML) ineligible for intensive induction chemotherapy (chemo): interim results from the phase 1/2 VICEROY study
10.1182/blood-2025-654 · 2025
Azacitidine, venetoclax, and revumenib for newly diagnosed NPM1-mutated or KMT2A-rearranged AML
10.1200/jco-25-00914 · 2025
Phase II Study of the all-oral combination of revumenib (SNDX-5613) with decitabine/cedazuridine (ASTX727) and venetoclax (SAVE) in newly diagnosed AML
10.1182/blood-2025-47 · 2025
A phase Ib/II study of ivosidenib with venetoclax±azacitidine in IDH1-mutated myeloid malignancies
10.1158/2643-3230.bcd-22-0205 · 2023
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML
10.1182/bloodadvances.2020001503 · 2020
Genetic and Phenotypic correlates of clinical outcomes with Venetoclax in Acute Myeloid Leukemia: the GEN-PHEN-VEN study
10.1158/2643-3230.bcd-24-0256 · 2025
Phase II study of venetoclax added to cladribine plus low-dose cytarabine alternating with 5-azacitidine in older patients with newly diagnosed acute myeloid leukemia
10.1200/jco.21.02823 · 2022
Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy
10.1182/bloodadvances.2025017083 · 2025
A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapy
10.1158/2159-8290.cd-22-1297 · 2023
Post-allogeneic hematopoietic cell transplantation outcomes are similar after hypomethylating agent/venetoclax and intensive, cytarabine-based remission induction for Acute Myeloid Leukemia when using standardized, contemporary transplant techniques
10.1182/blood-2025-44 · 2025
Optimizing lower intensity triplet therapy in acute myeloid leukemia: a practical guide
10.1038/s41408-025-01429-z · 2025
No additional external references are available.